Company Overview
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.17.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +128.20% |
| 6 Months: | +58.40% |
| 3 Months: | +77.94% |
| 1 Month: | +68.86% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross3d ago
- RSI (14)69.42 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MNPR Monopar Therapeutics Inc. R2K | 99.79 | -51.70 | $668.50M | 0.00% | -12.11% | -15.86% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | 0 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 |
| Operating Income | -373.84K | -594.96K | -14.90M | -897.26K | -667.53K | -667.53K | - | -1.41M | -932.11K | -759.45K | -1.14M | -1.46M | -1.65M | -1.89M | -2.09M | -2.46M | -2.46M | -2.76M | -2.41M | -2.53M | -2.33M | -2.07M | -1.72M | -1.79M | -1.57M | -3.22M | -3.23M | -4.09M | -5.23M |
| Net Income | -372.92K | -591.44K | -14.88M | -876.35K | -640.18K | -640.18K | -890.46K | -1.38M | -905.70K | -736.08K | -1.09M | -1.45M | -1.64M | -1.88M | -2.08M | -2.46M | -2.46M | -2.76M | -2.40M | -2.43M | -2.20M | -1.95M | -1.64M | -1.72M | -1.30M | -2.62M | -2.45M | -3.44M | -3.89M |
| R&D Expense | 133.74K | 311.59K | 180.68K | 457.14K | 303.68K | 303.68K | - | 835.60K | 329.29K | 219.85K | 344.41K | 832.50K | 1.26M | 1.21M | 1.48M | 1.83M | 1.68M | 2.08M | 1.73M | 1.65M | 1.59M | 1.32M | 966.11K | 1.13M | 984.28K | 1.64M | 1.73M | 2.59M | 3.49M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | - | - | - | - | 0 | 0 |
| Operating Income | -1.19M | -16.60M | -3.33M | -4.32M | -6.51M | -9.13M | -10.54M | -8.83M | -16.16M | -16.70M |
| Net Income | -1.19M | -16.55M | -3.23M | -4.22M | -6.30M | -9.10M | -10.52M | -8.40M | -15.59M | -13.72M |
| R&D Expense | 280.36K | 935.32K | 1.77M | 1.97M | 4.07M | 6.49M | 7.59M | 5.60M | 13.01M | 9.90M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.90M | 9.93M | 7.32M | 13.35M | 16.87M | 20.52M | 13.23M | 7.35M | 60.29M | 140.72M |
| Total Equity | 2.75M | 2.83M | 9.62M | 6.92M | 12.63M | 15.69M | 18.94M | 10.09M | 5.59M | 55.04M | 137.83M |
| Cash & Equivalents | - | 2.07M | 8.98M | 6.89M | 13.21M | 16.74M | 20.30M | 8.19M | 7.27M | 45.82M | 61.83M |
| Total Liabilities | - | 64.51K | 311.87K | 399.55K | 724.16K | 1.18M | 1.58M | 3.14M | 1.76M | 5.25M | 2.89M |
| Current Liabilities | - | 64.51K | 311.87K | 399.55K | 724.16K | 1.18M | 1.58M | 3.13M | 1.76M | 5.25M | 2.74M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -1.19M | -2.63M | -2.68M | -3.02M | -4.66M | -7.32M | -7.23M | -7.86M | -6.40M | -12.20M |
| Investing Cash Flow | - | - | - | - | - | 0 | -4.92M | 4.93M | -14.34M | -63.45M |
| Financing Cash Flow | 1.26M | 9.54M | -206.27K | 9.35M | 8.18M | 10.88M | 32.87K | 2.03M | 59.29M | 91.57M |
| Share Buybacks | - | - | - | - | - | - | - | - | 0 | 35.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| ROE % | -41.9% | -172.1% | -46.7% | -33.5% | -40.2% | -48.1% | -104.2% | -150.4% | -28.3% | -10.0% |
| ROCE % | -42.1% | -172.6% | -48.1% | -34.2% | -41.5% | -48.2% | -104.3% | -158.0% | -29.4% | -12.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Janus Henderson Group PLC | 19.67% | 1.32M | $129.90M |
| 2 | RA Capital Management, L.P. | 9.96% | 667.21K | $65.79M |
| 3 | Saturn V Capital Management LP | 5.16% | 345.63K | $34.08M |
| 4 | Deerfield Management Company, L.P | 4.83% | 323.75K | $31.92M |
| 5 | Blackrock Inc. | 4.73% | 316.57K | $31.21M |
| 6 | Adage Capital Partners GP L.L.C. | 4.62% | 309.19K | $30.49M |
| 7 | Siren, L.L.C. | 4.03% | 270.12K | $26.63M |
| 8 | Adar1 Capital Management, LLC | 3.95% | 264.28K | $26.06M |
| 9 | Polar Capital Holdings PLC | 3.38% | 226.53K | $22.34M |
| 10 | Vanguard Capital Management LLC | 3.26% | 218.46K | $21.54M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MNPR
MNPR (MNPR): Arthur Klausner files Form 144/A to sell 5,000 shares - Stock Titan
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNdXJiVFkwNzRvak8tZzdSMGpubW4xc0hrTkVseFhXVXRiUDMzQndxWDdlcjEyRlNLSVZ4dDdyWXhIaVZLQWwtZGtldUtPSmxucEEzV1Nsckcta2c3eWRZMjlDQl9sZDFScEZDT3BjdnU4VHd0cnR4VWcxRS1sZ3JRTUVLNHZ2aUpZZ3NlaW…
MNPR Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE04YUlIZ0tCam52ZVlSOXVFLWVCVGxGOFpORUxoUnlHWWw3N3Y1VkgxMW9meUhBRy1SQ053ZWU2STZmTjlUWHlPeUVFdU4yM19HYjFUeTBVRF9VNEJ5LUlEU1pCWDF2OG1lOWM1V1g4R3JzdGl4TzYwanJ3?oc=5" target="_blank">MNP…
Wall Street Analysts Believe Monopar Therapeutics (MNPR) Could Rally 88.92%: Here's is How to Trade - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQazhHbUNWQ3pYZ2RkVzNmMHJWenZMUURsZGFIT0tGWHplX2hMY3huYlFydXBYcXAwQTZ0d1IwZnl0LU5TTVgybnd1M3RaRG5lZWd0VW0xS0V4NDk0UHFsS0p0VTI1MDIzS1lkejNYaUhBS2JCc3JmQTRLdTVpZ2Q5ODRKMnVuLWpydFYyOH…
(MNPR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMixAFBVV95cUxQUURkdmFSaGtFN1dqNGVkYjNIbWJpblY1MmcySjVIbUVkeUp0ZWg4azlNbFFOVmtqeGtDZVNrYWVBRy1MWTdhcUNCYmN6VWMwUnNObmVZSW1DYVRQbmtueHJZNmlydUotcmR0elVia1B4elowYTBTN2N1TDV2ODdRVGNoOF9ZUi1mU1pNWW…
Biotech Stocks At 52-Week Highs: TRAX, BBIO, MNPR, TXG, MPLT - RTTNews
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOc1F1MmEzOGJ3T1VBaHJ1YVdPMWt3d3VtQTQtX1ZQS1lXOXRUWmw3aE9FTWRJYnlUdS1oSVh6QUtkOVdtbWlLMmo0RjUweWhSSDNGZUo5dlVQa0FSd0FGaEloNlR4d21wYnFWUTF1c1kzc1pzaENOSEpId2EtbV9aVE1hVk5SaWY2bEFIVm…
$MNPR stock is up 9% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxPZzZFTHYyV2p3dWNFLUM5NjRONWExd29RS0E1Rks2ejd1UWptS1NLRlgzMHZNS2l4OUpZdWZwR1JPeXRkQmctTjNCbVkzUTJNNlJxVXVBcWlzbmNHTm9pN296Mm1IQThONFF6dzFxVlo1ZUExcXlaS1F0NExXd2xaXzVOaURDOVdUY09Hbn…
MNPR — Frequently Asked Questions
What is the current share price of Monopar Therapeutics Inc. (MNPR)?
As of 2026-07-14 21:23 PDT, Monopar Therapeutics Inc. (MNPR) trades at $99.79 on NasdaqCM. Its 52-week range is $30.42 to $106.60.
What is the market capitalisation of MNPR?
Monopar Therapeutics Inc. (MNPR) has a market capitalisation of $668.50M on NasdaqCM.
What is the P/E ratio of MNPR?
MNPR trades at a trailing price-to-earnings (P/E) ratio of -51.70. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.90.
What is the return on equity (ROE) of MNPR?
MNPR has a return on equity (ROE) of -15.86%. Its return on capital employed (ROCE) is -12.11%.
Is MNPR a good stock to buy?
This page provides a data-driven analysis of Monopar Therapeutics Inc. (MNPR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.